Adlai Nortye Group Ltd. (ANL) Form 6-K — Sep 8, 2026
Adlai Nortye Group Ltd. dosed the first patient in Australia with AN4035, initiating a global Phase I trial in patients with CEACAM5-enriched RAS-addicted solid tumors, and received a Study-May-Proceed letter from the U.S. FDA clearing its IND to expand the trial into the United States. AN4035 is a first-in-class antibody-drug conjugate targeting CEACAM5 and armed with a pan-RAS(ON) inhibitor payload from the company's proprietary RASiCA platform, designed for tumor-selective RAS pathway inhibition while sparing normal tissue.
Key figures
- Phase1a Data Readout
- second half of 2027
- Preclinical Cytotoxicity
- nanomolar to picomolar in CEACAM5-positive, RAS-addicted cancer cell lines
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.